Los Angeles, CA – May 31, 2015 – NantHealth, a cloud-based information technology company, and NantOmics, a leading medical diagnostic company, both wholly owned subsidiaries of NantWorks, today provided information on the presentation of two abstracts at the 2015 American Society of Clinical Oncology (ASCO) annual meeting, May 29 to June 2, 2015, in Chicago.
Abstract #11005
- Title: “Protein expression by genetic mutations identified in gene panels (hotspots) and efficacy of targeted treatments.”
- Session: June 1, 3 p.m. – 6 p.m. CT. Location: E450. Oral presentation: 4:24 p.m. – 4:36 p.m. CT, by Eric Collisson, M.D.
Abstract #11093
- Title: “Genomics, transcriptomics and proteomics in the clinical setting: Integrating whole genome, whole exome and RNA sequencing with quantitative proteomics to better inform clinical treatment selection.”
- Session: May 31, 8 a.m. – 11:30 a.m. CT. Location: S Hall A, Board #307. Presenter: Shahrooz Rabizadeh, Ph.D.
Additional information can be found on the 2015 ASCO annual meeting website.
“Genetic mutations in gene panels (hotspots) do not always result in protein expression,” said Eric Collisson, M.D., Hematology/Oncology, UC San Francisco. “Using a cloud-based integrated analysis of genomic (DNA) and transcriptomic (RNA) sequencing data provides insight into downstream protein expression that analysis of tumor only DNA sequencing alone, cannot.”
“Today, the approach widely used by oncologists to guide therapy selection is to identify mutations in the DNA of a patient’s tumor, using a limited number of ‘actionable’ genes,” said Patrick Soon-Shiong, M.D., founder and chief executive officer of NantHealth. “This approach leads to both false-positive and false-negative results. Including RNA data and analysis of the whole genome may lead to improved identification of clinically-actionable targets, and, ultimately, the selection of better treatment options.”
About NantOmics
NantOmics is a leading medical diagnostic company dedicated to providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information visit www.nantomics.com.
About NantHealth
NantHealth, a member of the NantWorks ecosystem of companies, is a transformational healthcare cloud-based IT company converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care, in the time of need, anywhere, anytime. NantHealth works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The company’s technology empowers physicians, patients, payers and researchers to transcend the traditional barriers of today’s healthcare system. By converging molecular science, near real-time patient signal monitoring, computer science and big data technology, the NantHealth Clinical Operating System (cOS) platform empowers physicians, patients, and payers to coordinate best care, monitor outcomes and control cost in real time. This is the first system of its kind in healthcare, enabling 21st century coordinated care at a lower cost, enabling value-based population health management at a single patient level and at the population at large. For more information please visit www.nanthealth.com.